---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-000908"
form_type: "8-K"
ticker: "BFRI"
cik: "0001858685"
company_name: "Biofrontera Inc."
filed_at: "2023-01-09T23:59:59+00:00"
generated_at: "2026-06-20T18:16:44.528868+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Biofrontera reports preliminary Q4 2022 revenue of ~$10.2-10.4M, up 12% YoY; FY2022 record $28.7-28.9M

## Summary
- Preliminary Q4 2022 revenue $10.2-10.4M, an increase of approximately 12% vs Q4 2021.
- Full year 2022 revenue of $28.7-28.9M, a record high and up ~20% compared to 2021.
- CEO Erica Monaco cites continued expansion of Ameluz-PDT for actinic keratosis as driver.
- Final Q4 and FY2022 financial results expected in March 2023.

## SEC filing metadata
- accession: 0001493152-23-000908
- form_type: 8-K
- ticker: BFRI
- cik: 0001858685
- company_name: Biofrontera Inc.
- filed_at: 2023-01-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1858685/000149315223000908/0001493152-23-000908-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1858685/000149315223000908/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-000908
- JSON: https://secwatch.observer/filing/0001493152-23-000908.json
- Plain text: https://secwatch.observer/filing/0001493152-23-000908.txt

## Key facts
- Earnings Releases
  Biofrontera Inc. reported fourth quarter and year ended December 31, 2022 results: revenue $10.2 million to $10.4 million.
  - Period: fourth quarter and year ended December 31, 2022
  - Revenue: $10.2 million to $10.4 million
  - Result: preliminary results
  source text: Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced preliminary, unaudited revenues for the three and 12 months ended December 31, 2022. Revenues for the fourth quarter of 2022 are anticipated to be in the range of approximately $10.2 million to $10.4 million, an increase of approximately 12% compared with the fourth quarter of 2021. These projections result in 2022 revenue of approximately $28.7 million to $28.9 million, a record high and up approximately 20% compared with 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1858685/000149315223000908/0001493152-23-000908-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.